NRG
DNLI icon

Nemes Rush Group’s Denali Therapeutics DNLI Stock Holding History

Nemes Rush Group’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$13.4K Hold
700
– – ﹤0.01% 512
2025
Q4 		$11.6K Hold
700
– – ﹤0.01% 531
2025
Q3 		$10.2K Hold
700
– – ﹤0.01% 485
2025
Q2 		$9.79K Hold
700
– – ﹤0.01% 478
2025
Q1 		$9.52K Hold
700
– – ﹤0.01% 469
2024
Q4 		$14.3K Hold
700
– – ﹤0.01% 432
2024
Q3 		$14.4K Hold
700
– – ﹤0.01% 371
2024
Q2 		$16.3K Hold
700
– – ﹤0.01% 364
2024
Q1 		$14.4K Hold
700
– – ﹤0.01% 408
2023
Q4 		$15K Hold
700
– – ﹤0.01% 385
2023
Q3 		$14.4K Hold
700
– – ﹤0.01% 367
2023
Q2 		$20.7K Buy
+700
New +$19.7K ﹤0.01% 363

Other funds holding DNLI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Nemes Rush Group's DNLI Position: Q1 2026 in Review

Nemes Rush Group held its Denali Therapeutics (DNLI) position steady in Q1 2026 at 700 shares worth $13.4K. The position accounts for ﹤0.01% of the portfolio, ranked #512.

Nemes Rush Group first reported a position in DNLI in Q2 2023 and has held it in 12 quarters since. The position peaked at $20.7K in Q2 2023. 269 funds tracked by Wall St. Rank hold DNLI as of Q1 2026.

  • Nemes Rush Group held 700 shares of Denali Therapeutics worth $13.4K as of Q1 2026.
  • Nemes Rush Group left its Denali Therapeutics share count unchanged in Q1 2026.
  • Denali Therapeutics made up ﹤0.01% of Nemes Rush Group's portfolio in Q1 2026, its #512 holding.
  • Nemes Rush Group first reported a position in Denali Therapeutics in Q2 2023 and has held it in 12 quarters since.
  • Nemes Rush Group's Denali Therapeutics position peaked at $20.7K in Q2 2023.
  • 269 funds tracked by Wall St. Rank held Denali Therapeutics as of Q1 2026.

Based on Nemes Rush Group's 13F filing for Q1 2026, filed 21 Apr 2026.